Longitudinal Changes in Urinary ExoQuick-TC-Enriched Fraction-Derived Tryptic Peptides Following Thyroidectomy in Well-Differentiated Thyroid Cancer: The t-UXEDO Study
Life · 11.11.2026 · 16 (11) · 1906
DOI: 10.3390/life16111906 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 11.11.2026. Verfasst von Yuan-Yu Tsai und 5 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council.
Abstract (Originalsprache)
Background
Differentiated thyroid cancer generally has a favorable prognosis; however, postoperative surveillance remains important because persistent or recurrent disease may occur. Urinary fractions enriched by extracellular-vesicle precipitation methods represent a potential noninvasive source of proteomic biomarkers, although these preparations may contain co-isolated non-vesicular proteins. We investigated longitudinal changes in tryptic surrogate peptides measured from an ExoQuick-TC-enriched urinary fraction following thyroidectomy in patients with well-differentiated thyroid cancer.
Methods
This prospective single-center exploratory study included 21 patients with papillary or follicular thyroid carcinoma. The clinical study was initiated in 2017, following earlier analytical development. Urine samples were collected before thyroidectomy and at five postoperative time points through 24 months. Predefined tryptic surrogate peptides were quantified using targeted liquid chromatography–multiple reaction monitoring tandem mass spectrometry (LC-MRM/MS). Available preoperative and 1-week postoperative paired urinary peptide measurements were reanalyzed using two-sided exact Wilcoxon signed-rank tests, with exploratory Benjamini–Hochberg false-discovery-rate (BH-FDR) adjustment.
Results
Twenty-one patients were included in the final analysis; the median age was 49 years, and 18 (85.7%) were women. No clinical recurrence was observed during 24 months of follow-up. Several urinary fraction-derived tryptic surrogate peptides exhibited variable postoperative patterns. Among patients with lymph-node metastasis, Keratin-19 showed a nominal early postoperative decrease (exact p = 0.0156). In the I-131-treated subgroup, Keratin-19 also demonstrated a nominal postoperative association (exact p = 0.0176), whereas Calprotectin A8 did not reach nominal statistical significance (exact p = 0.0676). None of these associations remained statistically significant after BH-FDR adjustment within the 12 urinary peptide targets available for exact reanalysis.
Conclusions
Longitudinal targeted proteomic measurements from an ExoQuick-TC-enriched urinary fraction demonstrated exploratory postoperative changes in selected tryptic surrogate peptides. These observations do not establish exosome-specific biomarker performance, disease specificity, or recurrence-prediction utility. Larger prospective studies with standardized analytical procedures and independent validation are warranted.
Förderung
- National Science and Technology Council
Zitieren
APA
Tsai, Y., Wang, C., Shih, S., Chen, K., Chung, Y., & Huang, P. (2026). Longitudinal Changes in Urinary ExoQuick-TC-Enriched Fraction-Derived Tryptic Peptides Following Thyroidectomy in Well-Differentiated Thyroid Cancer: The t-UXEDO Study. Life, 16(11), 1906. https://doi.org/10.3390/life16111906
Vancouver
Tsai Y, Wang C, Shih S, Chen K, Chung Y, Huang P. Longitudinal Changes in Urinary ExoQuick-TC-Enriched Fraction-Derived Tryptic Peptides Following Thyroidectomy in Well-Differentiated Thyroid Cancer: The t-UXEDO Study. Life. 2026;16(11):1906. doi:10.3390/life16111906
BibTeX
@article{Tsai2026,
author = {Tsai, Yuan-Yu and Wang, Chih-Yuan and Shih, Shyang-Rong and Chen, Kuen-Yuan and Chung, Yi-Chieh and Huang, Pei-Jie},
title = {Longitudinal Changes in Urinary ExoQuick-TC-Enriched Fraction-Derived Tryptic Peptides Following Thyroidectomy in Well-Differentiated Thyroid Cancer: The t-UXEDO Study},
journal = {Life},
year = {2026},
volume = {16},
number = {11},
pages = {1906},
doi = {10.3390/life16111906}
}
EUVIMED